Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briquilimab-Based Conditioning for HCT in GATA2 Deficiency
NCT05907746Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of briquilimab in GATA2 deficiency (GATA2D), sponsored by National Cancer Institute. Started Nov 2023; status: active, not recruiting.
02
Drugs
briquilimab
03
Conditions
GATA2 deficiency (GATA2D)
Beyond the preview
Go deeper on NCT05907746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907746.